Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
about
New treatments for genotype 1 chronic hepatitis C - focus on simeprevirOutcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantationHepatitis C in Argentina: epidemiology and treatment.Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionTelaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.Update on Hepatitis C Virus and HIV Coinfection.Recent advances in management of the HIV/HCV coinfected patient.Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.Treating HCV in HIV 2013: on the cusp of change.Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new.Optimal management of patients with chronic hepatitis C and comorbidities.Blood-borne viral co-infections among human immunodeficiency virus-infected inmates.Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients.Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals.Reply to Menard et al.
P2860
Q26853138-E35AD154-40A3-437C-80D8-B388DA4F1434Q26864478-9D00157B-1154-40D1-8849-2D8195956153Q33706886-9F37B6BA-7897-472E-9D43-97EA18186E94Q34298877-289FFB61-8666-4AC3-A126-162652585D7CQ35607785-3E55C323-C0DE-4634-B738-70CF863A3896Q35906047-A3FB55D6-D92C-432D-B6B6-8BFBFD415DDCQ36575497-45504437-CE9C-447E-A0F6-F91A8FB40C5FQ36654120-C2457DF4-010B-4257-9326-68BBCB354FE5Q38174250-7A2A66E5-438C-4688-9945-FFADCE30E0DFQ38238013-FD4CE60C-51AB-4C82-A3F6-3D7A2E4AF2D4Q38295819-9E70DBC4-8BC9-42A2-982E-520703601A35Q39739900-F2F71FB7-1B9D-4DB8-A2F6-881BA2B49DEEQ40775611-3B3E28EF-16A9-4DA8-8002-FA77EFA42432Q40840459-E4D0F5D6-8496-4026-882B-DDA7DF7F258EQ40856847-6A0291C3-32AA-4A15-8B49-AF0E13C4614FQ54689847-4EC71ACA-8F73-4CEB-914D-C17F1937F099
P2860
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Virological response rates for ...... h and without HIV coinfection.
@en
Virological response rates for ...... h and without HIV coinfection.
@nl
type
label
Virological response rates for ...... h and without HIV coinfection.
@en
Virological response rates for ...... h and without HIV coinfection.
@nl
prefLabel
Virological response rates for ...... h and without HIV coinfection.
@en
Virological response rates for ...... h and without HIV coinfection.
@nl
P2093
P2860
P356
P1433
P1476
Virological response rates for ...... h and without HIV coinfection.
@en
P2093
Dt Dieterich
K Bichoupan
M Sulkowski
P Perumalswami
S Brinkley
Td Schiano
V Martel-Laferrière
P2860
P304
P356
10.1111/HIV.12086
P577
2013-09-11T00:00:00Z